Provectus Q2 Loss Narrows 47% but Going Concern Doubt Persists
PVCT sits 56% above its 52-week low of $0.038.
Summary
Provectus narrowed its Q2 loss to $988,716 but still faces a going concern warning with only $1.16 million in cash and a $6.3 million working capital deficit.
Key Events · Earnings and Guidance · PVCT
-
Q2 Loss Narrows 47%
Net loss was $988,716 for Q2 2026, down from $1,852,081 a year earlier, driven by an 85% cut in R&D spending to $131,130.
-
Cash Position Improves but Remains Critical
Cash rose to $1,156,915 from $251,291 at year-end, but the working capital deficit is $6,338,261 and the going concern warning is reiterated.
-
Convertible Note Financing Continues
The company received $1,360,000 in 2025 Notes proceeds in Q2, with $1,245,000 from non-related parties and $115,000 from related parties.
-
Debt and Fees Converted to Preferred Stock
$540,000 of principal and $43,434 of interest converted into 203,859 Series D-1 Preferred shares; $542,501 of accrued directors' fees converted into 189,554 shares.
Analysis · PVCT · Life Sciences
A 46.6% improvement in Provectus Biopharmaceuticals' Q2 2026 net loss, to $988,716, was driven by an 85% cut in R&D spending. Cash rose to $1.16 million from $251,291 at year-end, yet the company still faces a $6.3 million working capital deficit and reiterates substantial doubt about its ability to continue as a going concern. During the quarter, $1.36 million was raised in convertible notes, and debt and director fees were converted into preferred stock, adding to potential dilution. With the stock trading at $0.0594 and 420 million shares outstanding, the cash runway is extremely tight.
At the time of this filing, PVCT was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $25M. The 52-week trading range was $0.04 to $0.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.